Related Experiment Video
Updated: Mar 23, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth
Sung S Choi1, Byung Hoon Chi2, In Ho Chang2
1Biomedical Research Institute, Chung-Ang University Hospital, Seoul, Republic of Korea.
Abstract:
Bladder cancer is a significant clinical and economic problem. Despite intravesical chemotherapy and immunotherapy, up to 80% of patients with non-muscle-invasive bladder cancer develop recurrent tumors, of which 20% to 30% evolve into more aggressive, potentially lethal tumors. Recently, bladder cancer cells are considered to be mediators of resistance to current therapies and therefore represent strong candidates as biologic targets. No effective chemotherapy has yet been developed for advanced bladder cancer. It is desirable that a drug can be delivered directly and specifically to bladder cancer cells. Stem cells have selective migration ability toward cancer cells, and therapeutic genes can be easily transduced into stem cells. In suicide gene therapy for cancer, stem cells carry a gene encoding a carboxylesterase (CE) enzyme that transforms an inert CPT-11 prodrug into a toxic SN-38 product, a topoisomerase 1 inhibitor. In immunodeficient mice, systemically transplanted HB1.F3.CE stem cells migrated toward the tumor implanted by the TCCSUP bladder cancer cell line, and, in combination with CPT-11, the volume of tumors was significantly reduced. These findings may contribute to the development of a new selective chemotherapeutic strategy against bladder cancer. Mol Cancer Ther; 15(6); 1201-7. ©2016 AACR.
Insights
Stem cells carrying a suicide gene target bladder cancer cells, converting a chemotherapy prodrug into a potent toxin. This novel approach significantly reduced tumor volume in mice, offering a promising new bladder cancer treatment strategy.
Area of Science:
- Oncology
- Gene Therapy
- Cancer Biology
Background:
- Bladder cancer recurrence is high despite current treatments, with some cases progressing to lethal forms.
- Bladder cancer cells can mediate resistance to therapies, highlighting the need for targeted biologic approaches.
- Developing effective chemotherapy for advanced bladder cancer remains a challenge, necessitating targeted drug delivery.
Purpose of the Study:
- To investigate the potential of engineered stem cells for targeted bladder cancer therapy.
- To evaluate a novel suicide gene therapy approach using stem cells to deliver a cytotoxic agent specifically to bladder cancer cells.
Main Methods:
- Systemic transplantation of HB1.F3.CE stem cells engineered to express carboxylesterase (CE) in immunodeficient mice bearing TCCSUP bladder cancer cell line tumors.
- Administration of CPT-11 prodrug, which is converted by CE into the active cytotoxic drug SN-38.
- Monitoring of stem cell migration towards tumor sites and assessment of tumor volume reduction.
Main Results:
- Engineered stem cells (HB1.F3.CE) demonstrated selective migration towards bladder cancer cells in vivo.
- Combination therapy of stem cells and CPT-11 significantly reduced tumor volume compared to controls.
- This approach showed potential for targeted delivery of a toxic agent to bladder cancer.
Conclusions:
- Stem cell-mediated suicide gene therapy offers a potential new strategy for selective chemotherapeutic treatment of bladder cancer.
- Targeting bladder cancer cells with engineered stem cells and prodrug activation may overcome limitations of current therapies.
- These findings support further development of this approach for clinical application against bladder cancer.
More Related Videos
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
08:43Culture, Manipulation, and Orthotopic Transplantation of Mouse Bladder Tumor Organoids
Published on: January 31, 2020